Erenumab is under clinical development by Amgen and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Erenumab’s likelihood of approval (LoA) and phase transition for Trigeminal Neuralgia (Tic Douloureux) took place on 15 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Erenumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Erenumab overview

Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human immunoglobulin G2 (IgG2) monoclonal antibody. It is formulated as solution in a single-dose for sub-cutaneous route of administration. Erenumab is indicated for the preventive treatment of migraine in adults.

Erenumab (AMG-334) is under development for the treatment of chronic cluster headache, an episodic migraine and chronic migraine. The drug candidate is administered intravenously or subcutaneously as form an of a solution.

It is under development for rosacea, temporomandibular disorder (TMD) pain, migraine in adults and pediatric patients,  persistent headache attributed to mild traumatic brain injury (persistent post-traumatic headache) and trigeminal neuralgia. It was also under development for the treatment of hot flashes associated with menopause and stable angina.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

Quick View Erenumab LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Erenumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Women’s Health
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.